Brokerages Set Quest Diagnostics Incorporated (NYSE:DGX) Price Target at $142.36

Shares of Quest Diagnostics Incorporated (NYSE:DGX) have received a consensus rating of “Buy” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $142.36.

Several research analysts have weighed in on the stock. Robert W. Baird reiterated a “neutral” rating and issued a $137.00 price target on shares of Quest Diagnostics in a research report on Thursday, March 18th. UBS Group raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $135.00 to $158.00 in a research note on Tuesday, May 4th. Mizuho increased their price objective on shares of Quest Diagnostics from $149.00 to $158.00 and gave the stock a “buy” rating in a research note on Wednesday, May 12th. Finally, Morgan Stanley increased their price objective on shares of Quest Diagnostics from $130.00 to $136.00 and gave the stock an “equal weight” rating in a research note on Friday, March 12th.

DGX opened at $128.18 on Tuesday. The company has a quick ratio of 1.63, a current ratio of 1.76 and a debt-to-equity ratio of 0.59. Quest Diagnostics has a 1-year low of $103.26 and a 1-year high of $142.80. The company has a market capitalization of $16.75 billion, a P/E ratio of 9.73, a PEG ratio of 0.43 and a beta of 1.04. The stock has a 50 day simple moving average of $131.39.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, April 22nd. The medical research company reported $3.76 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.77 by ($0.01). Quest Diagnostics had a return on equity of 29.42% and a net margin of 17.43%. The business had revenue of $2.72 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the business posted $0.94 earnings per share. The firm’s revenue was up 49.3% on a year-over-year basis. As a group, research analysts expect that Quest Diagnostics will post 11.21 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 21st. Shareholders of record on Wednesday, July 7th will be paid a $0.62 dividend. The ex-dividend date is Tuesday, July 6th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 1.93%. Quest Diagnostics’s payout ratio is currently 22.18%.

In other Quest Diagnostics news, SVP Catherine T. Doherty sold 8,536 shares of Quest Diagnostics stock in a transaction on Friday, May 7th. The shares were sold at an average price of $139.96, for a total value of $1,194,698.56. Following the completion of the transaction, the senior vice president now directly owns 68,729 shares of the company’s stock, valued at approximately $9,619,310.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael E. Prevoznik sold 44,939 shares of Quest Diagnostics stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $137.00, for a total transaction of $6,156,643.00. Following the completion of the transaction, the senior vice president now directly owns 85,091 shares of the company’s stock, valued at $11,657,467. The disclosure for this sale can be found here. Company insiders own 1.45% of the company’s stock.

Several large investors have recently modified their holdings of the business. Private Ocean LLC bought a new stake in shares of Quest Diagnostics in the 1st quarter worth about $25,000. GPS Wealth Strategies Group LLC bought a new stake in shares of Quest Diagnostics in the 1st quarter worth about $36,000. Freedman Financial Associates Inc. bought a new stake in shares of Quest Diagnostics in the 4th quarter worth about $42,000. First Mercantile Trust Co. bought a new stake in shares of Quest Diagnostics in the 4th quarter worth about $48,000. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Quest Diagnostics by 43.0% in the 1st quarter. Quadrant Capital Group LLC now owns 379 shares of the medical research company’s stock worth $49,000 after acquiring an additional 114 shares during the last quarter. 87.34% of the stock is owned by institutional investors and hedge funds.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading: How to invest in blue-chip stocks

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.